DekaBank Deutsche Girozentrale Buys 367 Shares of United Therapeutics Corporation $UTHR

DekaBank Deutsche Girozentrale increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 0.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,532 shares of the biotechnology company’s stock after purchasing an additional 367 shares during the period. DekaBank Deutsche Girozentrale’s holdings in United Therapeutics were worth $26,571,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of UTHR. Nuveen LLC bought a new position in shares of United Therapeutics in the first quarter worth approximately $83,533,000. Amundi boosted its stake in United Therapeutics by 198.8% in the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after buying an additional 232,988 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in United Therapeutics in the second quarter worth approximately $55,746,000. Acadian Asset Management LLC boosted its stake in United Therapeutics by 1,657.8% in the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock worth $55,217,000 after buying an additional 169,010 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in United Therapeutics by 46.1% in the first quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock worth $143,381,000 after buying an additional 146,664 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold 322,935 shares of company stock valued at $133,361,282 over the last 90 days. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on UTHR. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley upped their target price on United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Wells Fargo & Company assumed coverage on United Therapeutics in a research note on Monday. They set an “underweight” rating and a $414.00 price objective for the company. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Finally, Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $461.62.

United Therapeutics Stock Down 0.2%

Shares of UTHR stock opened at $421.64 on Thursday. The stock has a fifty day moving average of $393.00 and a 200 day moving average of $330.45. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The firm has a market capitalization of $19.02 billion, a price-to-earnings ratio of 16.46, a PEG ratio of 4.60 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business’s revenue was up 11.7% compared to the same quarter last year. During the same period in the previous year, the business earned $5.85 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.